Filing Details

Accession Number:
0001415889-24-025381
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-10-17 17:06:43
Reporting Period:
2024-10-15
Accepted Time:
2024-10-17 17:06:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1672619 Enliven Therapeutics Inc. ELVN () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1584759 A. Richard Heyman C/O Enliven Therapeutics, Inc.
6200 Lookout Road
Boulder CO 80301
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-10-15 1,270 $27.67 124,490 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 37,407 Indirect See footnote
Common Stock 27,918 Indirect See footnote
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023.
  2. This transaction was executed in multiple trades at prices ranging from $27.1521 to $27.9631. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  3. The shares are held of record by the Richard A. Heyman and Anne E. Daigle Trust, dated November 1, 2016 for which the Reporting Person serves as trustee.
  4. The shares are held of record by RAHD Capital LLC for which the Reporting Person serves as a managing member.